Precision Therapeutics, Rosetta Genomics sales and marketing update

Rosetta and Precision launched the miRview mets2 assay in the U.S. to identify the primary origin of tumor of uncertain or unknown origin. miRview mets2 is a microRNA-based test that identifies the primary origin of 42 different tumor types. Precision has co-commercialization rights in the U.S. to miRview mets2 from Rosetta (see BioCentury, July 30). ...